000			01610nam a2200181Ia 4500
003			MX-MdCICY
005			20250625162410.0
040			_cCICY
090			_aB-18347
245	1	0	_aEngineering a new generation of hemostatic agents: highlights of the Scientific Session on Hemostasis at the 2013 meeting of the American Society of Hematology.
490	0		_vExpert Review of hematology, 7(3), p.343-345, 2014
520	3		_aThis article is a review of the program organized by the Scientific Committee on Hemostasis entitled 'Engineering a New Generation of Hemostatic Agents', at the American Society of Hematology 2013 annual meeting. This field is one in which high quality basic research is currently being translated into novel therapeutics to manage bleeding and improve the quality of life for persons with hemophilia and their families. The program focused on three examples of novel strategies for improving therapeutics for hemophilia: engineering more effective procoagulant molecules based on a detailed understanding of coagulation factor structure/function relationships; prolonging the circulating lifetime of coagulation factor therapeutics and utilizing therapies that target a coagulation inhibitor to allow hemostatic clot formation even in the presence of low or absent levels of FVIII or FIX.
650	1	4	_aHEMOSTATIC AGENTS
700	1	2	_aHoffman, M.
856	4	0	_uhttps://drive.google.com/file/d/1iOdj5YmHCvK-EFBP-uilUR5mcmuR_GR6/view?usp=drivesdk _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx
942			_2Loc _cREF1
008			250602s9999 xx |||||s2 |||| ||und|d
999			_c52499 _d52499